A new flavor of company is shaking up how biotechs are built. Instead of launching with eye-popping early-stage science or a new platform, there’s a

A Swiss biotech with two experimental medicines from China, plus an in-house discovery team, has brought in $165 million to advance into late-stage testing. The

Belgian biotech UCB has made its second acquisition of the year, buying T-cell engager player Candid Therapeutics for up to $2.2 billion.

Bristol Myers Squibb is warming up for the FIFA World Cup 2026 with a new media campaign, launching its “Won’t Lose” ad ahead of the

Arvinas and Pfizer’s Veppanu is the first PROTAC – and third oral SERD for breast cancer – to be approved by the FDA.